药品
药理学
传统医学
医学
体内
体外
维罗细胞
药物发现
冠状病毒
病毒学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019年冠状病毒病(COVID-19)
生物
病毒
传染病(医学专业)
疾病
生物信息学
生物化学
生物技术
病理
作者
Mya Myat Ngwe Tun,Kazufumi Toume,Elizabeth Luvai,Khine Mya Nwe,Shusaku Mizukami,Kenji Hirayama,Kenshi Komatsu,Kouichi Morita
标识
DOI:10.1007/s11418-021-01596-w
摘要
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 2019 has led to a global health crisis. Mutations of the SARS-CoV-2 genome have impeded the development of effective therapeutics and vaccines against SARS-CoV-2. Natural products are important for discovering therapeutics to treat the 2019 coronavirus disease (COVID-19). In the present study, we investigated the antiviral activity of herbal drug extracts from Polygala Root, Areca, and Quercus Bark and natural compounds derived from herbal drug such as baicalin and glabridin, with IC50 values of 9.5 µg/ml, 1.2 µg/ml, 5.4 µg/ml, 8.8 µM, and 2.5 µM, respectively, against SARS CoV-2 infection in vitro. Certain herbal drug extracts and natural compounds were found to inhibit viral RNA levels and infectious titers of SARS-CoV-2 in a dose-dependent manner. Furthermore, viral protein analyses showed that herbal drug extracts and natural compounds effectively inhibited SARS-CoV-2 in the various entry treatments. Our study revealed that three herbal drugs are good candidates for further in vivo and clinical studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI